Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats

…, F Soldner, D Hockemeyer, PJ Hallett… - Proceedings of the …, 2010 - National Acad Sciences
Recent advances in deriving induced pluripotent stem (iPS) cells from patients offer new
possibilities for biomedical research and clinical applications, as these cells could be used for …

[PDF][PDF] Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease

PJ Hallett, M Deleidi, A Astradsson, GA Smith… - Cell stem cell, 2015 - cell.com
Autologous transplantation of patient-specific induced pluripotent stem cell (iPSC)-derived
neurons is a potential clinical approach for treatment of neurological disease. Preclinical …

Rationale for and use of NMDA receptor antagonists in Parkinson's disease

PJ Hallett, DG Standaert - Pharmacology & therapeutics, 2004 - Elsevier
N-Methyl-d-aspartate (NMDA) glutamate receptors are a class of excitatory amino acid
receptors, which have several important functions in the motor circuits of the basal ganglia, and …

Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking

PJ Hallett, R Spoelgen, BT Hyman… - Journal of …, 2006 - Soc Neuroscience
Interactions between dopaminergic and glutamatergic afferents in the striatum are essential
for motor learning and the regulation of movement. An important mechanism for these …

Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

PJ Hallett, AW Dunah, P Ravenscroft, S Zhou… - …, 2005 - Elsevier
The development of dyskinesias and other motor complications greatly limits the use of
levodopa therapy in Parkinson's disease (PD). Studies in rodent models of PD suggest that an …

[HTML][HTML] Long-term health of dopaminergic neuron transplants in Parkinson's disease patients

PJ Hallett, O Cooper, D Sadi, H Robertson, I Mendez… - Cell reports, 2014 - cell.com
To determine the long-term health and function of transplanted dopamine neurons in
Parkinson's disease (PD) patients, the expression of dopamine transporters (DATs) and …

[HTML][HTML] Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons

…, JR McLean, SC Izen, E Perez-Torres, PJ Hallett… - Neurobiology of …, 2015 - Elsevier
Diminished lysosomal function can lead to abnormal cellular accumulation of specific
proteins, including α-synuclein, contributing to disease pathogenesis of vulnerable neurons in …

Sustained systemic glucocerebrosidase inhibition induces brain α-synuclein aggregation, microglia and complement C1q activation in mice

…, SC Izen, E Perez-Torres, PJ Hallett… - Antioxidants & redox …, 2015 - liebertpub.com
Aims: Loss-of-function mutations in GBA1, which cause the autosomal recessive lysosomal
storage disease, Gaucher disease (GD), are also a key genetic risk factor for the α-…

The Toll-like receptor-3 agonist polyinosinic: polycytidylic acid triggers nigrostriatal dopaminergic degeneration

M Deleidi, PJ Hallett, JB Koprich… - Journal of …, 2010 - Soc Neuroscience
In Parkinson's disease (PD), loss of striatal dopaminergic (DA) terminals and degeneration
of DA neurons in the substantia nigra (SN) are associated with glial reactions. Such …

[HTML][HTML] Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease

…, DA Priestman, O Isacson, PJ Hallett… - Molecular …, 2019 - Springer
Background Haploinsufficiency in the Gaucher disease GBA gene, which encodes the
lysosomal glucocerebrosidase GBA, and ageing represent major risk factors for developing …